Research teams from the Department of Energy’s Oak Ridge National Laboratory and their technologies have received seven 2021 R&D 100 Awards, plus special recognition for a COVID-19-related project.
ORNL's Larry Baylor and Andrew Lupini have been elected fellows of the American Physical Society.
Diego Del-Castillo-Negrete, a distinguished staff member in the Fusion Energy Division, was cited for Outstanding Technical Achievement – National Laboratory. He will be recognized during the GMiS annual conference, which will be held virtually Oct. 11-22. The HENAAC awards program is in its 33rd year.
ORNL has licensed its wireless charging technology for electric vehicles to Brooklyn-based HEVO. The system provides the world’s highest power levels in the smallest package and could one day enable electric vehicles to be charged as they are driven at highway speeds.
A new tool that simulates the energy profile of every building in America will give homeowners, utilities and companies a quick way to determine energy use and cost-effective retrofits that can reduce energy and carbon emissions.
Joseph Pickel has been elected a 2021 fellow of the American Chemical Society, or ACS. Pickel supports the Fusion and Fission Energy and Sciences Directorate as environment, safety and health
Kathy McCarthy, associate laboratory director for Fusion and Fission Energy and Science at the Department of Energy’s Oak Ridge National Laboratory, has been elected fellow of the American Nuclear Society for her nationally and internationally recognized leadership in nuclear energy and fusion.
The Department of Energy’s Office of Science has selected five Oak Ridge National Laboratory scientists for Early Career Research Program awards.
The Department of Energy’s Oak Ridge National Laboratory has licensed its award-winning artificial intelligence software system, the Multinode Evolutionary Neural Networks for Deep Learning, to General Motors for use in vehicle technology and design.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.